Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs

Parasitology Research

Volumn 90, Issue SUPPL. 2, 2003, Pages

  Kayser, O ^a   Olbrich, C ^b   Croft, S L ^c   Kiderlen, A F ^d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMBELCET; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIPARASITIC AGENT; APHIDICOLIN; ARTEMISIN; ATOVAQUONE; BETA CYCLODEXTRIN; BUPARVAQUONE; CAMPTOTHECIN; CHLORAMBUCIL; CHLOROQUINE; CYCLODEXTRIN; KETOCONAZOLE; LIPOSOME; METHOTREXATE; MILTEFOSINE; NIFURTIMOX; NIOSOME; PAROMOMYCIN; PENTAMIDINE; PHOSPHATIDYLCHOLINE; PIPERINE; PLUMBAGIN; POLY(ETHYL 2 CYANOACRYLATE); POLYSORBATE 80; STARCH; STIBOGLUCONATE SODIUM; SURFACTANT; UNINDEXED DRUG;

COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; NONHUMAN; PARASITOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TABLET FORMULATION;

ANIMALS; ANTIPARASITIC AGENTS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EMULSIONS; HUMANS; LIPIDS; LIPOSOMES; PARASITIC DISEASES; PARTICLE SIZE; SURFACE-ACTIVE AGENTS;

PROTOZOA;

EID: 0037963716     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-002-0769-2     Document Type: Review

References (87)

1. Alving CR (1983) Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther 22:407-424
2. Armitage K, Flanigan T, Carey J, Frank I, MacGregor RR, Ross P, Goodgame R, Turner J (1992) Treatment of cryptosporidiosis with paromomycin. A report of five cases. Arch Intern Med 152:2497-2499
3. Baillie AJ, Coombs GH, Dolan TF, Hunter CA, Laakso T, Sjoholm I, Starnkvist P (1987) Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. J Pharm Pharmacol 39:832-835
4. Banerjee G, Nandi G, Mahatoo SB, Pakrashi A, Basu MK (1996) Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 38:145-150
5. Bauer K, Frömming K-H, Führer C (2000) Pharmazeutische Technologie. Wissenschaftliche Verlagsgesellschaft, Stuttgart
6. Berman JD, Edwards N, King M, Grogl M (1989) Biochemistry of Pentostam resistant Leishmania. Am J Trop Med Hyg 40: 159-164
7. Borchard G, Audus K, Shi F, Kreuter J (1994) Uptake of surfactant coated poly(methyl)methacrylate nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 110:29-35
8. Carvalhaes MS, Santana JM, Nobrega OT, Aragao JB, Grellier P, Schrevel J, Teixeira AR (1998) Chemotherapy of an experimental Trypanosoma cruzi infection with specific immunoglobulin-chlorambucil conjugate. Lab Invest 78:707-714
9. Castro-Hermida JA, Gonzalez-Losada Y, Freire-Santos F, Mezo-Menendez M, Ares-Mazas E (2001a) Evaluation of beta-cyclodextrin against natural infections of cryptosporidiosis in calves. Vet Parasitol 101:85-89
10. Castro-Hermida JA, Quilez-Cinca J, Lopez-Bernad F, Sanchez-Acedo C, Freire-Santos F, Ares-Mazas E (2001b) Treatment with beta-cyclodextrin of natural Cryptosporidium parvum infections in lambs under field conditions. Int J Parasitol 31:1134-1137
11. Cauchetier E, Paul, M, Rivollet D, Fessi H, Astier A, Deniau M (2000) Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of routine leishmaniasis. Int J Parasitol 30:777-783
12. Chakraborty R, Dasgupta D, Adhya S, Basu MK (1999). Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania. Biochem J 340:393-396
13. Chavanet P (1997) Amphotericin B deoxycholate (Fungizone): old drug, new versions. Rev Med Interne 18:153-165
14. Chimanuka B, Gabriels M, Detaevernier MR, Plaizir-Vercammen JA (2002) Preparation of beta-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chaubaudi malaria-infected mice. J Pharm Biomed Anal 28:13-22
15. Coukell AJ, Brogden RN (1998). Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55:585-612
16. Croft SL, Davidson RN, Thornton EA (1991) Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 28 [Suppl B]:111-118
17. Dingler A, Blum RP, Niehus H, Müller RH, Gohla S (1999) Solid lipid nanoparticles (SLN/Lipopearls) - a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 16:751-767
18. Dorea EL, Yu L, De Castro I, Campos SB, Ori M, Vaccari EM, Lacaz C, Seguro AC (1997) Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion. J Am Soc Nephrol 8:1415-1422
19. Escobar P, Yardley V, Croft SL (2001) Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45:1872-1875
20. Frömming K-H (1997) Cyclodextrine - eine vielseitig verwendbare Gruppe neuer Hilfsstoffe. In: Müller R, Hildebrand G (eds) Moderne Arzneiformen. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 17-21
21. Fusai T, Boulard Y (1997) Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model. Parasite 4:133-139
22. Gangneux JP, Sulahian A (1996) Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg 90:574-577
23. Garnier T, Croft SL (2002). Topical treatment for cutaneous leishmaniasis. Curr Opin Invest Drugs 3:538-544
24. Gonzalez-Martin G, Merino I (1998) Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. J Pharm Pharmacol 50:29-35
25. Gonzalez-Martin G, Figueroa C, Merino I, Osuna A (2000) Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity. Eur J Pharm Biopharm 49:137-142
26. Grogl M, Schuster BG, Ellis WY, Berman JD (1999) Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol 85:354-359
27. Guru PY, Agrawal AK (1989) Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett 245:204-208
28. Hrckova G, Velebny S (2001) Treatment of Toxocara canis infections in mice with liposome-incorporated benzimidazole carbamates and immunmodulator glucan. J Helminthol 75:141-146
29. Just-Nubling G (1994) Therapy of candidiasis and cryptococcosis in AIDS. Mycoses 37 [Suppl 2]:56-63
30. Kayser O (2000) Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. Int J Pharm 196:253-256
31. Kayser O (2001) A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int J Pharm 214:83-85
32. Kayser O, Keithly J (2000) Nanosuspensions as potential drug delivery system for aurones, a new group of natural products for the treatment of cryprosporidiosis. Proceedings of the third world meeting of pharmaceutical technology. pp413-414
33. Kayser O, Kiderlen A, Gelderblom H (2001) Aufnahme von Wirkstoff-Nanopartikeln in Leishmania donovani infizierten Makrophagen. Dtsch Apoth Z 141:1836-1838
34. Kreuter J (1983a) Evaluation of nanoparticles as drug-delivery systems. II: Comparison of the body distribution of nanoparticles with the body distribution of microspheres (diameter greater than 1 micron), liposomes, and emulsions. Pharm Acta Helv 58:217-226
35. Kreuter J (1983b) Evaluation of nanoparticles as drug-delivery systems. III: materials, stability, toxicity, possibilities of targeting, and use. Pharm Acta Helv 58:242-250
36. Kreuter J (1991) Liposomes and nanoparticles as vehicles for antibiotics. Infection 19:S224-228
37. Kreuter J (1994) Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet 19:253-256
38. Kreuter J (1995) Nanoparticulate systems in drug delivery and targeting. J Drug Target 3:171-173
39. Kreuter J (1996). Nanoparticles and microparticles for drug and vaccine delivery. J Anat 189:503-505
40. Lamothe J (2001) Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. J Small Anim Pract 42:170-175
41. Lehr CM, Haas J (2002) Developments in the area of bioadhesive drug delivery systems. 2:287-298
42. Mandal TK (1999) Effect of solvent on the characteristics of pentamidine loaded microcapsule. J Biomater Sci Polym 10:1-17
43. Maurin M, Raoult D (1996). Optimum treatment of intracellular infection. Drugs 52:45-59
44. McKellar QA (1994) Chemotherapy and delivery systems - helminths. Vet Parasitol 54:249-258
45. Meyerhoff A (1999) U S Food and Drug Administration approval of AmBiosome (liposomal amphotericin B) for treatmentod visceral leishmaniasis. Am J Trop Med Hyg 40: 159-164
46. Müller RH (1991) Colloidal carriers for controlled drug delivery and targeting. Wissenschaftliche Verlagsgesellschaft, Stuttgart
47. Müller R, Böhm B (1998) Nanosuspensions. In: Müller R, Böhm B, Benita S (eds) Nanosuspensions. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Medpharm Scientific, Stuttgart, pp149-173
48. Müller R, Peters K (1998) Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int J Pharm 160:229-237
49. Müller RH, Maassen S, Weyhers H, Mehnert W (1996) Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 4:161-170
50. Müller RH, Rühl D, Runge S, Lück M, Paulke BR (1997). Influence of fluorescent labelling of polystyrene particles on phagocytic uptake, surface hydrophobicity, and plasma protein adsorption. Pharm Res 14:18-24
51. Müller RH, Rühl D, Runge S, Schulze-Förster K, Mehnert W (1997b) Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 14:458-462
52. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161-177
53. Müller RH, Jacobs C, Kayser O (2001) Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3-19
54. Naresh RA, Udupa N, Devi PU (1996) Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J Pharm Pharmacol 48:1128-1132
55. Navin TR, Juranek DD (1984) Cryptosporidiosis: clinical, epidemiologic, and parasitologic review. Rev Infect Dis 6:313-327
56. Oliva G, Gradoni L, Ciaramella P, De Luna R, Cortese L, Orsini S, Davidson RN, Persechino A (1995) Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 36:1013-1019
57. O'Neil MG, Lapointe M (1997) Administration of amphotericin B in lipid emulsion. Crit Care Med 25:892-893
58. Pahissa A (1997) Amphotericin B. Lipid complex versus liposomes. Which, why, when? Enferm Infecc Microbiol Clin 15:1-3
59. Panosian CB, Barza M, Szoka F, Wyler DJ (1984) Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob Agents Chemother 25:655-656
60. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G (1975). Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 394:483-491
61. Paul, M, Durand, R, Boulard Y, Fusai T, Fernandez C, Rivollett D, Deniau M, Astier A (1998) Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 5:481-490
62. Peeters PA, Huiskamp CW, Eling WM, Crommelin DJ (1989) Chloroquine containing liposomes in the chemotherapy of murine malaria. Parasitology 3:381-386
63. Petit N, Parola P, Dhiver C, Gastaut JA (1996) Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients. J Antimicrob Chemother 38:154-157
64. Proulx ME, Desormeaux A, Marquis JF, Olivier M, Bergeron MG (2001) Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 45:2623-2627
65. Pyle R (1981) Clinical pharmacology of amphotericin B. J Am Vet Med Assoc 179:83-84
66. Raay B, Medda S, Mukhopadhyay S, Basu MK (1999) Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis. Indian J Biochem Biophys 36: 248-251
67. Ramos H, Brajtburg J, Marquez V, Cohen BE (1995) Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Drugs Exp Clin Res 21:211-216
68. Ranchere JY, Latour JF, Fuhrmann C, Lagallarde C, Loreuil F (1996) Amphotericin B intralipid formulation: stability and particle size. J Antimicrob Chemother 37:1165-1169
69. Roberts WL, Hariprashad J, Rainey PM, Murray HW (1996) Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis. Am J Trop Med Hyg 55:444-446
70. Rodrigues JMJr, Croft SL, Fessi H, Bories C, Devissaguet JP (1994) The activity and ultrastructure localization of primaquine-loaded poly (d,l-lactide) nonoparticles in Leishmania donovani infected mice. Trop Med Parasitol 45:223-228
71. Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, Perlin DS (2000) Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 44:2356-2360
72. Schöler N, Krause K, Kayser O, Müller RH, Borner K, Hahn H, Liesenfeld O (2001a) Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 45:1771-1779
73. Schöler N, Olbrich C, Tabatt K, Müller RH, Hahn H, Liesenfeldt O (2001b) Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm 221:57-67
74. Segovia M, Navarro A, Artero JM (1989) The effect of liposome-entrapped desferrioxamine on Leishmania donovani in vitro. Ann Trop Med Parasitol 83:357-360
75. Seifert K, Duchene M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann G, Hottkowitz T, Eibl H (2001) Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 45:1505-1510
76. Sen N, Samanta A, Baidya S, Gupta BK, Ghosh LK (1998) Development of amphotericin B loaded nanoparticles. Boll Chim Farm 137:295-297
77. Sievers TM, Kubak BM, Wong-Beringer A (1996) Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother 38:333-347
78. Sinha J, Mukhopadhyay S, Das N, Basu MK (2000) Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Deliv 7:209-213
79. Soto J, Hernandez N, Meija H, Grogl M, Berman J (1995) Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/ methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 20:47-51
80. Sundar S (2001) Liposomal amphotericin B. Lancet 357:801-802
81. Tachibana H, Yoshihara E, Kaneda Y, Nakae T (1988) In vitro lysis of the blood stream forms of Trypanosoma brucei gambiense by stearylamine-bearing liposomes. Antimicrob Agents Chemother. 32:966-970
82. Valladares JE, Riera C, Gonzalez-Ensenyat P, Diez-Cascon A, Ramos G, Solano-Gallego L, Gallego M, Portus M, Arboix M, Alberola J (2001) Long term improvement in the treatment of canine leishmaniasis using an antimony liposomal formulation. Vet Parasitol 97:15-21
83. Venier-Julienne MC, Benoit, JP (1996) Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm Acta Helv 71:121-128
84. Walker SA, Kennedy MT, Zasadzinski JA (1997) Encapsulation of bilayer vesicles by self-assembly. Nature 387:61-64
85. Weldon JS, Munnell JF, Hanson WL, Alving CR (1983) Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Z Parasitenkd 69:415-424
86. Wong JW, Yuen KH (2001) Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins. Int J Pharm 227:177-185
87. Yardley V, Croft S (2000) A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 13:243-248